COVID-19 EHR DREAM Challenge
The rapid rise of COVID-19 has challenged healthcare globally. Due to the importance and emergent need for better understanding of the condition and the development of patient specific clinical risk scores and early warning tools, we have developed a platform to support testing analytic and machine learning hypotheses on clinical data without data sharing as a platform to rapidly discover and implement approaches for care. This Challenges aims to identify risk factors that lead to a positive test utilizing electronic health recorded data mapped to the OMOP Common Data Model. REGISTER NOW
CTD^2 Pancancer Chemosensitivity DREAM Challenge
Current round: Pre-competition
Registration Open: April 20, 2020
Webinar: April 28, 2020 Click here for attendance options.
Launch: April 28, 2020
Leaderboard Round Opens: April 28, 2020
Leaderboard Round Closes: June 29, 2020, 5PM Pacific Time
Final Round Opens: June 29, 2020, 5PM Pacific Time
Final Round Closes: July 27, 2020, 5PM Pacific Time
Winners Announced: August, 2020
The goal of this Challenge is to foster development and benchmarking of algorithms to predict the sensitivity, as measured by the area under the dose-response curve, of a cell line to a compound based on the baseline transcriptional profiles of the cell line.
Metadata Automation DREAM Challenge
Open Phase: Ends 2/9/2020
Leaderboard Phase Round 1: 2/10/2020 - 3/9/2020
Leaderboard Phase Round 2: 3/10/2020 - 4/9/2020
Validation Phase: 4/10/2020 - 4/24/2020
Winners Announced: early May 2020
We aim to significantly lower the burden of adding coherent metadata annotations across the data ecosystem to streamline and enable both retrospective harmonization as well as data query, discovery and interpretation. This challenge addresses this time-consuming task with automated metadata annotation of structured data.
CTD^2 Beat AML DREAM Challenge
Open Phase: Ends 1/6/2020
Webinar: 1/6/2020 11:00 AM PST
Leaderboard Phase: 1/6/2020 - 3/2/2020
Validation Phase: 3/2/2020 - 4/28/2020
Winners Announced: early May 2020
The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering (genomic and transcriptomic) biomarkers of drug sensitivity, as evaluated on an unpublished cohort of patients from the BeatAML project.
RA2 DREAM Challenge
Launch: November 4, 2019 (Now open)
Final Submissions: May 31, 2020
Winners Announced: July 31, 2020
Rheumatoid Arthritis (RA) is a debilitating disease that causes joint damage in the hands and feet due to inflammation. Accurate measuring of joint damage and progression of disease is essential in assessing the severity of disease, along with being able to monitor patient response to treatment. Scoring of X-ray images is tedious and there can be a great deal of variability between rheumatologists when applying scoring methods. We will leverage nearly 1000 images across a range of disease severities to challenge participants to develop an automated scoring algorithm with the goal of making clinical scoring fast and consistent; this will aid rheumatologists in making the best decisions for patients.
Designed and run by a community of researchers from a variety of organizations, DREAM Challenges invite participants to propose solutions to fundamental biomedical questions — fostering collaboration and building communities in the process. Sage Bionetworks provides the expertise and infrastructure to host challenges via their Synapse platform. Together, we share a vision allowing individuals and groups to collaborate openly so that the “wisdom of the crowd” provides the greatest impact on science and human health.
If you have an idea for a DREAM challenge, please contact us here.